Nexalis Therapeutics Limited

As of December 31, 2025, Nexalis Therapeutics Limited carries a market capitalization of 5.74M, placing it among publicly traded companies globally. Its enterprise value stands at 6.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Nexalis Therapeutics Limited has 239.36M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Nexalis Therapeutics Limited maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.09, indicating conservative leverage, while an interest coverage ratio of -18.13 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -168.58, reflecting losses generated across the asset base.

As of the close on October 13, 2026, Nexalis Therapeutics Limited's stock has declined approximately 73.34% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.

These figures cover the twelve months ended December 31, 2025. EBITDA reached -2.47M, while operating income came in at -2.47M.

As of December 31, 2025, Nexalis Therapeutics Limited holds 436,900.00 in cash and equivalents against 741,278.00 in total debt, resulting in a net debt position of 304,378.00. Total book value stands at -1.17M, with working capital of -858,508.00 providing operational flexibility.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield is negative at -19.67, meaning Nexalis Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nexalis Therapeutics Limited's most recent stock split took place on December 1, 2025 with a 137:138 split ratio.